Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
Clinical trial NCT03010176 · COMPLETED
Trial details
- NCT number
- NCT03010176
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-03
- Primary completion
- 2022-04-21
- Enrollment
- 156
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.